<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00163046</url>
  </required_header>
  <id_info>
    <org_study_id>A9451155</org_study_id>
    <nct_id>NCT00163046</nct_id>
  </id_info>
  <brief_title>A 28-Day Polysomnographic Study of Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 28-Day, Polysomnographic Study of Gabapentin 250 mg in Transient Insomnia Induced by a Sleep Phase Advance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to to assess the effect of gabapentin compared to placebo on
      sleep, using polysomnography along with subjective sleep assessments, in subjects with
      transient insomnia induced by a sleep phase advance.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Polysomnographic (PSG) measurement of Wake after Persistent Sleep Onset (WAPSO)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSG WAPSO</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSG Latency to Persistent Sleep (LPS)</measure>
    <time_frame>Days 1 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSG Sleep Onset Latency (SOL)</measure>
    <time_frame>Days 1 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSG Number of Awakenings (NAW)</measure>
    <time_frame>Days 1 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSG Wake after Sleep Onset (WASO)</measure>
    <time_frame>Days 1 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSG Total Wake Time (TWT) plus Stage 1 Sleep</measure>
    <time_frame>Days 1 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSG Wake Time During Sleep (WTDS)</measure>
    <time_frame>Days 1 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSG Total Sleep Time (TST)</measure>
    <time_frame>Days 1 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSG Sleep Efficiency (SE)</measure>
    <time_frame>Days 1 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSG Percent of Stages 1, 2, 3, 4 and REM sleep</measure>
    <time_frame>Days 1 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSG Percent Slow Wave Sleep (SWS, Stages 3&amp;4 combined)</measure>
    <time_frame>Days 1 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective SL</measure>
    <time_frame>Days 1 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective NA</measure>
    <time_frame>Days 1 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective WASO</measure>
    <time_frame>Days 1 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective TST</measure>
    <time_frame>Days 1 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective ASR</measure>
    <time_frame>Days 1 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective ASQ</measure>
    <time_frame>Days 1 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Karolinska Sleep Diary (KSD)-Sleep Quality Index</measure>
    <time_frame>Days 1 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KSD individual scores</measure>
    <time_frame>Days 1 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Days 1 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Through Day 32</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">256</enrollment>
  <condition>Transient Insomnia</condition>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Gabapentin 250 mg oral capsule 30 minutes prior to bedtime for 28 days</description>
    <arm_group_label>Gabapentin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo 30 minutes prior to bedtime for 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older with occasional sleeplessness in the month prior to screening

        Exclusion Criteria:

          -  Current treatment for, or recent history (within 2 years) of, a sleeping disorder
             including excessive snoring, obstructive sleep apnea or a chronic painful condition
             that interferes with the subject's sleep

          -  Currently taking or expected to take any of the following during trial: amphetamines,
             benzodiazepines, cocaine, marijuana, methaqualone, methadone, opiates, propoxyphene,
             barbiturates, and phencyclidine during their participation in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A9451155&amp;StudyName=A%2028-Day%20Polysomnographic%20Study%20of%20Gabapentin%20in%20Transient%20Insomnia%20Induced%20by%20a%20Sleep%20Phase%20Advance</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2005</study_first_posted>
  <last_update_submitted>April 23, 2008</last_update_submitted>
  <last_update_submitted_qc>April 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2008</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

